Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2006
08/29/2006US7098214 Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders
08/29/2006US7098213 three-ring saturated N-heterocyclic compounds in combination with one or more antiviral or other agents; in immunotherapy
08/29/2006US7098212 Piperazine derivatives
08/29/2006US7098211 Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
08/29/2006US7098210 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
08/29/2006US7098209 Phosphodiesterase inhibitors; cardiovascular disorders; erectile dysfunction; hypotensive agents; respiratory system diosrders; chronic obstructive pulmonary disease; congestive heart failure; antihistamines; antiallergens
08/29/2006US7098208 Inhibitors of Akt activity
08/29/2006US7098207 Imidazotriazinones and the use thereof
08/29/2006US7098206 Psychological disorders; antidepressants;
08/29/2006US7098204 Hymenialdisine or derivatives thereof in the manufacture of medicaments
08/29/2006US7098203 and selective serotonin reuptake inhibitors; 4-benzyloxymethyl-4-phenylazepanes; antidepressants; anxiety
08/29/2006US7098202 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
08/29/2006US7098201 Heteroaromatic derivatives having an inhibitory activity against HIV integrase
08/29/2006US7098200 Analgesics
08/29/2006US7098199 Administering a polycyclic sulfamate ester that is replaced with a sulfate group and incubated with a seroid sulphatase enzyme at 7.4 pH and 37 degrees C to provide a Km value of < 50 micrometers
08/29/2006US7098198 Administering ezetimibe, a glucuronide of ezetimibe, SCH 48461 or SCH 58053 as cholesterol absorption inhibitors; antitumor agents for the prostate, breasts, endometrium, and colon; can be coadministered with another anticarcinogenic agent
08/29/2006US7098197 An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides
08/29/2006US7098196 Regulators of the hedgehog pathway, compositions and uses related thereto
08/29/2006US7098195 Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
08/29/2006US7098194 Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
08/29/2006US7098193 Useful for the treatment of gastrointestinal conditions
08/29/2006US7098192 Antisense oligonucleotide modulation of STAT3 expression
08/29/2006US7098190 Formulations comprising antisense nucleotides to connexins
08/29/2006US7098189 Wound and skin care compositions
08/29/2006US7098188 Alkali and alkaline earth metal salts of topiramate
08/29/2006US7098012 DNA demethylase, therapeutic and diagnostic uses thereof
08/29/2006US7098004 Isolated polypeptide of the stratum corneum and its use
08/29/2006US7097998 Aβ42 lowering agents
08/29/2006US7097994 UDP-N-acetylglucosamine:galactose-β1,3-N-acetylgalactosamine-α-R/ (GlcNAc to GaINAc) β1-6 N-acetylglucosaminyltransferase, C2GnT3
08/29/2006US7097984 Binding receptors to oocytes; contraceptives
08/29/2006US7097864 topical or transdermal anlgesics comprising extracts from shrubs and herbs, glutamine and fat soluble ascorbyl palmitate in the form of vitamin c; antiinflammatory agents
08/29/2006US7097862 Methods of inhibiting tumor necrosis factor
08/29/2006US7097860 Administering solution containing magnesium, or compound thereof
08/29/2006US7097859 Indium supplement compositions and methods therefor
08/29/2006US7097851 Multilayer capsule comprises an adhesion site-controlling layer for attaching to a selected site in the intestines, a drug-carrying layer, a protecting layer for preventing from digestive juice; improve bioavailability due to a low absorption in the digestive tract; dosage forms
08/29/2006US7097849 Injectable aqueous dispersions of propofol
08/29/2006US7097848 Comprising clothianidin and one or more insecticides selected from abamectin, emamectin or emamectin benzoate, and methiocarb; use smaller amounts; applying on plants, crops in agricultures
08/29/2006US7097847 Process to prepare a skin softening composition
08/29/2006US7097838 Antagonists of HMG1 for treating inflammatory conditions
08/29/2006US7097834 Osteoprotegerin binding proteins
08/29/2006US7097831 α-Amylase-resistant starch for producing foodstuff and medicaments
08/29/2006US7097828 Waterproofing; mixture containing thickener, emulsifers
08/29/2006US7097827 Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
08/29/2006US7097825 Methods and reagents to acquire MRI signals and images
08/29/2006US7097823 Administering a RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID, or tetraazacyclododecanetetramethylenephosphonic acid (DOTMP); osteomyelitis treatment
08/29/2006US7097785 improving the hand or feel of the fabric; good oil repellency
08/29/2006CA2521980C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
08/29/2006CA2521958C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-pheyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
08/29/2006CA2402020C Pharmaceutical compositions
08/29/2006CA2396738C Thiazole derivatives as active superoxide radical inhibitors
08/29/2006CA2392271C Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
08/29/2006CA2373410C A2a receptor agonists
08/29/2006CA2342390C Sustained release ranolazine formulations
08/29/2006CA2342340C New sustained release oral formulations
08/29/2006CA2281684C Inhibition of cell-cell binding by lipid assemblies
08/29/2006CA2280905C Highly lipophilic camptothecin derivatives
08/29/2006CA2277914C New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising budesonide
08/29/2006CA2277891C New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
08/29/2006CA2277890C New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
08/29/2006CA2271306C Pharmaceutical suspension systems
08/29/2006CA2271166C Compositions and uses thereof
08/29/2006CA2270177C Transdermal administration of ment
08/29/2006CA2268195C Azaheterocyclylmethyl derivatives of 2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one
08/29/2006CA2258152C Novel aromatic derivatives substituted by a ribose, their method of preparation and application as medicine
08/29/2006CA2255615C Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
08/29/2006CA2255564C Aerodynamically light particles for pulmonary drug delivery
08/29/2006CA2247198C Topical pharmaceutical composition containing heparin
08/29/2006CA2240735C Process for production of piperidine derivatives
08/29/2006CA2240201C Process for the preparation of felodipine
08/29/2006CA2238845C Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, preparation thereof and therapeutical use thereof
08/29/2006CA2233677C A novel combination of a .beta.-receptor blocker and an opioid
08/29/2006CA2213996C Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
08/29/2006CA2212856C Benzopyran-containing compounds and method for their use
08/29/2006CA2201785C New carboxylic acid derivatives, their preparation and their use
08/29/2006CA2164842C Use of isovaleramide as a mild anxiolytic and mild sedative agent
08/29/2006CA2112779C Arylsulfonamido-substituted hydroxamic acids
08/29/2006CA2111836C Spin-trapping pharmaceutical compositions and methods for use thereof
08/25/2006CA2534927A1 Use of active compounds for the prophylaxis and treatment of parasitic infections in fish
08/24/2006WO2006089311A1 Vanilloid receptor ligands and their use in treatments
08/24/2006WO2006089301A2 Diaminophenothiazine compositions and uses thereof
08/24/2006WO2006089298A2 Pyrimidine-fused diazepine derivatives and indole-fused pteridines
08/24/2006WO2006089290A1 Combinations and modes of administration of therapeutic agents and combination therapy
08/24/2006WO2006089286A2 Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
08/24/2006WO2006089276A2 Pharmacokinetically improved compounds
08/24/2006WO2006089275A2 Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
08/24/2006WO2006089225A1 5- [4- (4- (2 -amino- 2 -methoxycarbonylethyl) phenoxy) benzilidene] thiazolidin-2 , 4-dion e derivatives and related compounds for reducing glucose, cholesterol and triglyceride levels in plasma
08/24/2006WO2006089221A2 Compounds inhibiting the aggregation of superoxide dismutase-1
08/24/2006WO2006089215A2 Pharmaceutical compositions and methods
08/24/2006WO2006089211A2 Combat/training antioxidant micronutrient formulation and method of administration
08/24/2006WO2006089177A2 Isoxazole combretastin derivatives for the treatment of disorders
08/24/2006WO2006089168A2 Methods for modulating ion channels
08/24/2006WO2006089167A1 Glucosamine materials
08/24/2006WO2006089164A1 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
08/24/2006WO2006089150A2 Antiangiogenic agents with aldesleukin
08/24/2006WO2006089130A1 Kappa opioid receptor ligands
08/24/2006WO2006089100A1 Benzoxazole carboxamides for treating cinv and ibs-d
08/24/2006WO2006089076A2 Thiazole amides, imidazole amides and related analogues
08/24/2006WO2006089070A2 Acne gel
08/24/2006WO2006089066A1 Combinations therapy for treatment of demyelinating conditions
08/24/2006WO2006089064A1 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody